1 asset in Thalamic Cancer
Therapeutic assets addressing Thalamic Cancer, rated under Floatz methodology v0.2 and sorted by current rating.
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
Olutasidenib Thalamic Cancer | Rigel Pharmaceuticals | P2 | CCC (53) |
Therapeutic assets addressing Thalamic Cancer, rated under Floatz methodology v0.2 and sorted by current rating.
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
Olutasidenib Thalamic Cancer | Rigel Pharmaceuticals | P2 | CCC (53) |